Abeona Therapeutics Inc. ABEO
We take great care to ensure that the data presented and summarized in this overview for ABEONA THERAPEUTICS INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding ABEO
View all-
Adage Capital Partners Gp, L.L.C. Boston, MA3.9MShares$23.4 Million0.04% of portfolio
-
Suvretta Capital Management, LLC New York, NY3.69MShares$22.1 Million0.85% of portfolio
-
Nantahala Capital Management, LLC New Canaan, CT3.53MShares$21.2 Million0.98% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny2.12MShares$12.7 Million0.01% of portfolio
-
Western Standard LLC Los Angeles, CA2.08MShares$12.5 Million7.9% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.97MShares$11.8 Million0.0% of portfolio
-
Vivo Capital, LLC Palo Alto, CA1.84MShares$11.1 Million2.0% of portfolio
-
Laurion Capital Management LP New York, NY1.31MShares$7.84 Million0.14% of portfolio
-
683 Capital Management, LLC New York, NY792KShares$4.75 Million0.31% of portfolio
-
Propel Bio Management, LLC Los Angeles, CA624KShares$3.74 Million3.45% of portfolio
Latest Institutional Activity in ABEO
Top Purchases
Top Sells
About ABEO
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A; ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-50X for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1974 and is headquartered in New York, New York.
Insider Transactions at ABEO
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 31
2025
|
Mark Alvino Director |
BUY
Grant, award, or other acquisition
|
Direct |
36,101
+26.44%
|
-
|
|
Jan 31
2025
|
Leila Alland Director |
BUY
Grant, award, or other acquisition
|
Direct |
36,101
+18.95%
|
-
|
|
Jan 31
2025
|
Bernhardt G Zeiher Director |
BUY
Grant, award, or other acquisition
|
Direct |
36,101
+43.37%
|
-
|
|
Jan 31
2025
|
Eric Crombez Director |
BUY
Grant, award, or other acquisition
|
Direct |
36,101
+43.37%
|
-
|
|
Jan 31
2025
|
Christine Berni Silverstein Director |
BUY
Grant, award, or other acquisition
|
Direct |
36,101
+21.28%
|
-
|
|
Jan 31
2025
|
Donald A. Wuchterl Director |
BUY
Grant, award, or other acquisition
|
Direct |
36,101
+19.34%
|
-
|
|
Jan 31
2025
|
Michael Amoroso Director |
BUY
Grant, award, or other acquisition
|
Direct |
36,101
+16.67%
|
-
|
|
Jan 31
2025
|
Faith L. Charles Director |
BUY
Grant, award, or other acquisition
|
Direct |
36,101
+19.42%
|
-
|
|
Jan 29
2025
|
Mark Alvino Director |
SELL
Open market or private sale
|
Direct |
4,000
-5.85%
|
$20,000
$5.38 P/Share
|
|
Jan 21
2025
|
Vishwas Seshadri Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
476,435
+25.66%
|
-
|
|
Jan 21
2025
|
Joseph Walter Vazzano Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
144,509
+22.09%
|
-
|
|
Jan 21
2025
|
Brendan M. O'Malley SVP, General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
115,607
+22.92%
|
-
|
|
Jan 21
2025
|
Mark Alvino Director |
SELL
Open market or private sale
|
Direct |
4,000
-5.53%
|
$20,000
$5.1 P/Share
|
|
Oct 16
2024
|
Vishwas Seshadri Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
251
-0.03%
|
$1,506
$6.54 P/Share
|
|
Sep 28
2024
|
Joseph Walter Vazzano Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
6,388
-1.72%
|
$31,940
$5.89 P/Share
|
|
Sep 28
2024
|
Vishwas Seshadri Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
18,798
-2.04%
|
$93,990
$5.89 P/Share
|
|
Sep 28
2024
|
Brendan M. O'Malley SVP, General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
6,579
-2.35%
|
$32,895
$5.89 P/Share
|
|
Sep 20
2024
|
Brendan M. O'Malley SVP, General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
496
-0.18%
|
$2,976
$6.02 P/Share
|
|
Aug 26
2024
|
Christine Berni Silverstein Director |
BUY
Grant, award, or other acquisition
|
Direct |
11,797
+10.8%
|
-
|
|
Aug 26
2024
|
Donald A. Wuchterl Director |
BUY
Grant, award, or other acquisition
|
Direct |
11,797
+9.34%
|
-
|
Last 12 Months Summary
| Grant, award, or other acquisition | 1.94M shares |
|---|---|
| Open market or private purchase | 42.8K shares |
| Payment of exercise price or tax liability | 101K shares |
|---|---|
| Open market or private sale | 59.7K shares |